Novavax/NVAX

$3.97

2.05%
-
1D1W1MYTD1YMAX

About Novavax

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Ticker

NVAX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Jacobs

Employees

1,543

Headquarters

Gaithersburg, United States

Novavax Metrics

BasicAdvanced
$544.42M
Market cap
-
P/E ratio
-$5.53
EPS
1.65
Beta
-
Dividend rate
$544.42M
1.65028
$11.36
$3.53
7.41M
0.7
0.674
-38.31%
-26.88%
0.553
-50.36%
33.76%
27.41%

What the Analysts think about Novavax

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
287.91% upside
High $38.00
Low $4.00
$3.97
Current price
$15.40
Average price target

Novavax Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-61.2% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$291.3M
55.86%
Net income
$-178.3M
36.42%
Profit margin
-61.2%
-12.48%

Novavax Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 221.19%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$3.41
$0.58
-$1.26
-$1.44
-
Expected
-$3.46
-$1.39
-$1.83
-$0.45
-$0.92
Surprise
-1.5%
-141.83%
-31.21%
221.19%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Novavax stock?

Novavax (NVAX) has a market cap of $544.42M as of April 21, 2024.

What is the P/E ratio for Novavax stock?

The price to earnings (P/E) ratio for Novavax (NVAX) stock is 0 as of April 21, 2024.

Does Novavax stock pay dividends?

No, Novavax (NVAX) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Novavax dividend payment date?

Novavax (NVAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Novavax?

Novavax (NVAX) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Novavax stock price target?

The target price for Novavax (NVAX) stock is $15.4, which is 287.91% above the current price of $3.97. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Novavax stock

Buy or sell Novavax stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing